Birdwatch Note
2025-01-12 20:58:31 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
The claims made about ivermectin and Fenbendazole efficacy against cancer, aren't supported by human clinical evidence. https://factcheck.afp.com/doc.afp.com.33E87YP https://www.politifact.com/factchecks/2023/feb/20/facebook-posts/no-proof-dog-deworming-drug-fenbendazole-can-cure/ https://www.healthline.com/health/pancreatic-cancer/fenbendazole-for-pancreatic-cancer#clinical-trials Most studies have been conducted in vitro or in animal models. https://pubmed.ncbi.nlm.nih.gov/29257278/ https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1251-7 https://www.nature.com/articles/s41523-021-00229-5 Ivermectin and Fenbendazole are not approved by the FDA for cancer treatment. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086156/
Written by 779B59B4B10A0EBA025B7B12684726669EF3523F29C2562086C8007F6615D2C6
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1878449395064033744
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1878547126348566807
- noteId - 1878547126348566807
- participantId -
- noteAuthorParticipantId - 779B59B4B10A0EBA025B7B12684726669EF3523F29C2562086C8007F6615D2C6
- createdAtMillis - 1736715511296
- tweetId - 1878449395064033744
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- The claims made about ivermectin and Fenbendazole efficacy against cancer, aren't supported by human clinical evidence. https://factcheck.afp.com/doc.afp.com.33E87YP https://www.politifact.com/factchecks/2023/feb/20/facebook-posts/no-proof-dog-deworming-drug-fenbendazole-can-cure/ https://www.healthline.com/health/pancreatic-cancer/fenbendazole-for-pancreatic-cancer#clinical-trials Most studies have been conducted in vitro or in animal models. https://pubmed.ncbi.nlm.nih.gov/29257278/ https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1251-7 https://www.nature.com/articles/s41523-021-00229-5 Ivermectin and Fenbendazole are not approved by the FDA for cancer treatment. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086156/
Note Ratings
rated at | rated by | |
2025-01-12 18:55:02 -0600 | Rating Details | |
2025-01-12 18:16:21 -0600 | Rating Details | |
2025-01-12 18:12:13 -0600 | Rating Details | |
2025-01-12 17:08:56 -0600 | Rating Details | |
2025-01-12 16:47:10 -0600 | Rating Details | |
2025-01-12 16:24:01 -0600 | Rating Details | |
2025-01-12 16:06:54 -0600 | Rating Details | |
2025-01-12 16:04:25 -0600 | Rating Details | |
2025-01-12 15:27:42 -0600 | Rating Details | |
2025-01-12 15:23:55 -0600 | Rating Details | |
2025-01-12 15:20:09 -0600 | Rating Details | |
2025-01-12 15:19:02 -0600 | Rating Details | |
2025-01-12 15:10:59 -0600 | Rating Details | |
2025-01-12 15:01:02 -0600 | Rating Details | |
2025-01-13 19:41:10 -0600 | Rating Details | |
2025-01-13 16:42:35 -0600 | Rating Details | |
2025-01-13 15:03:45 -0600 | Rating Details | |
2025-01-13 14:10:53 -0600 | Rating Details | |
2025-01-13 13:05:21 -0600 | Rating Details | |
2025-01-13 12:59:07 -0600 | Rating Details | |
2025-01-13 12:47:38 -0600 | Rating Details | |
2025-01-13 12:35:52 -0600 | Rating Details | |
2025-01-13 11:47:45 -0600 | Rating Details | |
2025-01-13 09:38:10 -0600 | Rating Details | |
2025-01-13 07:23:33 -0600 | Rating Details | |
2025-01-13 07:18:08 -0600 | Rating Details | |
2025-01-13 04:29:41 -0600 | Rating Details | |
2025-01-13 02:49:28 -0600 | Rating Details | |
2025-01-13 00:27:33 -0600 | Rating Details | |
2025-01-12 23:38:27 -0600 | Rating Details | |
2025-01-12 23:35:12 -0600 | Rating Details | |
2025-01-12 22:55:36 -0600 | Rating Details | |
2025-01-12 22:46:38 -0600 | Rating Details | |
2025-01-12 22:34:53 -0600 | Rating Details | |
2025-01-12 21:30:47 -0600 | Rating Details | |
2025-01-12 21:29:48 -0600 | Rating Details | |
2025-01-12 20:49:47 -0600 | Rating Details | |
2025-01-12 20:36:35 -0600 | Rating Details | |
2025-01-12 20:35:34 -0600 | Rating Details | |
2025-01-12 20:33:13 -0600 | Rating Details | |
2025-01-12 20:27:52 -0600 | Rating Details | |
2025-01-12 20:12:40 -0600 | Rating Details | |
2025-01-12 20:01:01 -0600 | Rating Details | |
2025-01-12 19:32:31 -0600 | Rating Details | |
2025-01-12 19:24:23 -0600 | Rating Details | |
2025-01-12 19:24:05 -0600 | Rating Details | |
2025-01-12 19:15:50 -0600 | Rating Details | |
2025-01-12 19:15:40 -0600 | Rating Details | |
2025-01-12 19:08:50 -0600 | Rating Details | |
2025-01-12 19:04:16 -0600 | Rating Details | |
2025-01-12 18:56:16 -0600 | Rating Details | |
2025-01-12 17:18:36 -0600 | Rating Details | |
2025-01-12 16:51:26 -0600 | Rating Details | |
2025-01-12 15:53:47 -0600 | Rating Details | |
2025-01-12 15:25:47 -0600 | Rating Details | |
2025-01-12 15:23:10 -0600 | Rating Details | |
2025-01-13 10:46:30 -0600 | Rating Details | |
2025-01-13 06:16:26 -0600 | Rating Details | |
2025-01-13 05:19:55 -0600 | Rating Details | |
2025-01-13 02:26:51 -0600 | Rating Details | |
2025-01-13 01:42:26 -0600 | Rating Details | |
2025-01-12 23:56:11 -0600 | Rating Details | |
2025-01-12 21:27:11 -0600 | Rating Details | |
2025-01-12 21:05:09 -0600 | Rating Details | |
2025-01-12 20:13:34 -0600 | Rating Details | |
2025-01-12 19:57:56 -0600 | Rating Details | |
2025-01-12 19:45:50 -0600 | Rating Details | |
2025-01-12 19:45:16 -0600 | Rating Details | |
2025-01-12 19:43:12 -0600 | Rating Details | |
2025-01-12 19:34:22 -0600 | Rating Details | |
2025-01-12 19:30:18 -0600 | Rating Details | |
2025-01-12 19:17:01 -0600 | Rating Details | |
2025-01-12 18:17:29 -0600 | Rating Details | |
2025-01-12 18:04:16 -0600 | Rating Details | |
2025-01-12 16:34:16 -0600 | Rating Details | |
2025-01-12 16:00:39 -0600 | Rating Details | |
2025-01-12 15:22:32 -0600 | Rating Details | |
2025-01-12 15:11:31 -0600 | Rating Details | |
2025-01-15 11:43:08 -0600 | Rating Details | |
2025-01-13 14:25:31 -0600 | Rating Details | |
2025-01-13 14:04:37 -0600 | Rating Details | |
2025-01-13 10:57:44 -0600 | Rating Details | |
2025-01-13 10:18:29 -0600 | Rating Details | |
2025-01-13 07:31:50 -0600 | Rating Details | |
2025-01-13 02:39:54 -0600 | Rating Details | |
2025-01-13 01:13:25 -0600 | Rating Details | |
2025-01-13 00:38:27 -0600 | Rating Details | |
2025-01-12 23:58:46 -0600 | Rating Details | |
2025-01-12 21:51:16 -0600 | Rating Details | |
2025-01-12 20:20:48 -0600 | Rating Details | |
2025-01-12 19:16:51 -0600 | Rating Details | |
2025-01-12 18:53:50 -0600 | Rating Details | |
2025-01-12 18:27:18 -0600 | Rating Details | |
2025-01-12 18:12:16 -0600 | Rating Details | |
2025-01-12 16:49:24 -0600 | Rating Details | |
2025-01-12 16:27:44 -0600 | Rating Details | |
2025-01-12 16:22:34 -0600 | Rating Details | |
2025-01-12 15:39:27 -0600 | Rating Details | |
2025-01-12 15:38:00 -0600 | Rating Details | |
2025-01-13 15:00:38 -0600 | Rating Details | |
2025-01-13 06:59:12 -0600 | Rating Details | |
2025-01-13 04:35:02 -0600 | Rating Details | |
2025-01-13 02:29:42 -0600 | Rating Details | |
2025-01-12 20:57:48 -0600 | Rating Details | |
2025-01-12 20:34:08 -0600 | Rating Details | |
2025-01-12 20:15:20 -0600 | Rating Details | |
2025-01-12 19:54:05 -0600 | Rating Details | |
2025-01-12 17:17:07 -0600 | Rating Details | |
2025-01-12 17:06:25 -0600 | Rating Details | |
2025-01-12 16:52:28 -0600 | Rating Details | |
2025-01-12 16:26:09 -0600 | Rating Details | |
2025-01-12 15:20:17 -0600 | Rating Details | |
2025-01-12 15:13:27 -0600 | Rating Details |